In 10 volunteers, the pharmacokinetics of ofloxacin {HOE 280, DL 8280; (+)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido-[1,2,3-deI [1, 4] 1.4 liters/kg of body weight) suggested effective diffusion into the extravascular space. High total and renal clearances indicated primarily renal excretion with additional elimination pathways, such as tubular secretion and extrarenal elimination. After oral administration, absorption was excellent, and the absolute bioavailability following 200 mg of ofloxacin could be calculated at >0.95. Maximal concentrations in serum were attained 1.2 to 1.9 h after dosing; areas under the curve increased in proportion to dose between 200 and 400 mg of oral ofloxacin. The amount of known metabolites (demethyl and N-oxide compounds) excreted in urine reached only 4.3% (intravenously) and 4.0% (orally). Transient headaches in some volunteers were the only side effects registered.
6-Fluoro-7-piperazino-4-quinolones are noteworthy both for the wide range and intensity of activities against gramnegative bacilli and cocci in vitro and the capacity to control experimentally induced systemic infections with selected bacteria when administered orally in well-tolerated doses (9, 15, 27) .
Ofloxacin {HOE 280, DL 8280; (±)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl) -7-oxo-7H-pyrido [1,2,3- de] [1, 4] benzoxacine-6-carboxylic acid} is a new quinolone carboxylic acid derivative showing a broad antimicrobial spectrum against gram-positive and gram-negative bacteria (1, 11, 17, 22, 27) . This substance was found to be more active than norfloxacin and pipemidic acid (22) , its in vitro antibacterial activity being almost comparable to those of gentamicin, tobramycin, and newer cephalosporins (9, 11, 27) . When first introduced, ofloxacin could only be administered orally, but recently a parenteral form was developed.
The purpose of this study was to investigate the pharmacokinetic properties of this quinolone after oral and intravenous (i.v.) administration of various doses to determine the bioavailability and metabolism of this drug.
(Part of this study was presented at the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., 28 September to 1 October 1986.)
MATERIALS AND METHODS
Volunteers. Eighteen healthy test subjects (nine females and nine males) with no known allergies to quinolone derivatives participated in the study. The study was divided into three groups (1, 25 and 50 mg i.v.; 2, 100 and 200 mg i.v.; 3, 200 and 400 mg orally) with 10 (2, 12, 16) , C(t) = Ae-'(t -t') + Be-P(' -to) -C(t)oeka(t -, where C(t) represents the concentration in serum at time t in milligrams per liter, A and B (in milligrams per liter) are the zero intercepts of the tangents (x and 3 with the ordinate, and ox and ,B (per minute) represent the slopes of the rapid initial and slow terminal distribution and elimination phases, respectively; ka is the absorption rate, and to is the lag time. After i.v. administration, open two-and threecompartment models were used, following the equations: C(t) = Ae`(t) + Be-a(') (open two-compartment model) and C(t) = Ae")') + Be-P(') + Ce-""), where C(t) represents the serum concentration at time t in milligrams per liter, A, B, and C (in milligrams per liter) are the zero intercepts of the tangents ox, 3, and y with the ordinate, and a and a (per minute) represent the slopes of the rapid initial, intermediate, and slow terminal distribution and elimination phases, respectively. The secondary pharmacokinetic parameters were calculated with the aid of these hybrid constants (A, B, and C and cx, 3, and y) (16) . The least-squares method was used to fit the regression curve to the experimentally obtained values of the serum concentration curve (after normalization of the serum concentrations to a mean body weight of 70.0 kg). The pharmacokinetic parameters (for each test subject individually) were calculated by the method of nonlinear regression analysis, using a program developed for pharmacokinetic applications. The duration of infusion was treated by the method of Loo and Riegelmann (21) .
The mathematical calculation of the constants and pharmacokinetic parameters was performed by standard methods as previously described (12, 13, 16, 20) . The Wilcoxon test for paired differences was used to distinguish the differences within the pharmacokinetic parameters. (Fig. 1) .
RESULTS
The pharmacokinetic parameters are shown in Fig. 2 .
Ofloxacin is eliminated mainly by the kidneys with high urinary recoveries and high renal clearances. The renal clearances (170 to 190 ml/min) were significantly above the mean creatinine clearances of our volunteers (105.4 ml/min), indicating additional tubular secretion of this quinolone. However, there is also a considerable extrarenal elimination mechanism, which can be seen by the roughly 21% extrarenal partition of the total clearance.
The predominant renal elimination of ofloxacin resulted in high urinary recoveries (73 to 82% of dose 24 h after infusion; Fig. 3 Fig. 3 and 4 . The 24-h urine recoveries of ofloxacin after 200 mg were 77.0% (i.v.) and 73.6% (oral), again underlining the optimal absorption characteristics of this quinolone.
Metabolites. Mean renal elimination of ofloxacin and its metabolites (demethyl ofloxacin and ofloxacin N-oxide) after 200 mg orally and i.v. is shown in Table 2 . We found no differences in the amount of metabolites excreted by the kidneys between oral and i.v. administration; thus, no firstpass effect can be assumed. Total renal drug excretion (ofloxacin plus metabolites) after 200 mg i.v. reached means of 81.3% of the dose after 24 (25, 50, 100 , and 200 mg) demonstrated a linear dose dependency of parenteral ofloxacin.
The biological half-lives (two-compartment model; ,Bphase) for parenteral ofloxacin could be calculated at 231 to 267 min, thus indicating the possibility of a twice-daily administration of ofloxacin.
Ciprofloxacin, another parenteral quinolone, has biological half-lives of between 180 and 260 min (3, 4, 8, 13, 25) , whereas biological half-lives of parenteral enoxacin (306 + 25 min [26] ) and parenteral pefloxacin (630 + 90 min) were longer (10, 26) .
Total and renal clearances of ofloxacin showed a smooth linear increase, with higher clearances in the lower dosage range, but the ratios of total/renal clearance remained constant. Only 14 to 21% of ofloxacin is eliminated by extrarenal mechanisms; thus, renal excretion is the leading elimination pathway resulting in high urinary concentrations and urinary recovery rates (73 to 82% of the dose per 24 h). Comparative data of ciprofloxacin indicate higher total and renal clearances as well as a higher amount of extrarenal elimination (33 to 38%) of this quinolone (4, 8, 13) .
High volumes of distribution are a specific characteristic of quinolones (9, 14) ; however, the different fluoroquinolones appear to differ in their distributions in body fluids. In this study, volumes of distribution (Varea) were calculated to be between 1.23 and 1.4 liter/kg of body weight for parenteral ofloxacin; comparative values for ciprofloxacin after 100 and 200 mg i.v. in our laboratory were higher (2.64 and 2.80 liter/kg [4] ), and in good agreement with data published by Bergan et al. (3) and Drusano et al. (8) .
Ofloxacin binding to human serum proteins determined at different concentrations in serum was relatively low (25%) and similar to that of other fluoroquinolones (10, 13, 14, 24) .
Oral kinetics. There are only limited data in the literature of the oral pharmacokinetics of ofloxacin in volunteers (7, 19, 25; A. Saito and M. Tomizawa, 13th Int. Congr. Chemother., p. 125/13-125/16, 1983). Maximal concentrations in serum were relatively high after oral administration of 200 and 400 mg of ofloxacin and peaked at 77 and 115 min, respectively. Only Saito and Tomizawa (13th ICC) have reported on the pharmacokinetics of doses identical to those in our study. They found the same concentrations in serum for a dose of 200 mg but higher concentrations after administration of 400 mg of ofloxacin. Since prolonged biological half-lives (5.5 h) could be calculated, high concentrations in serum could be measured over a time period of 12 h after administration. The AUC following 200 and 400 mg of ofloxacin orally demonstrated a linear increase.
Calculations of the AUC after 200 mg of ofloxacin i.v. and orally showed nearly the same results, thus indicating an excellent absolute bioavailability (95 to 100%) of ofloxacin following oral administration.
Volumes of distribution and renal clearance following the administration of oral ofloxacin were in the same range as those after parenteral administration. More than 73% of the ofloxacin dosages were excreted by the kidneys within 24 h after intake. Ofloxacin has by far the highest urinary excretion after oral administration of all new quinolones; these recovery rates vary among 4% for pefloxacin, 27% for norfloxacin, 31% for ciprofloxacin, and 61% for enoxacin (26) .
Biotransformation. Ofloxacin undergoes only limited me- tabolism with urinary excretion of two metabolites (demethyl ofloxacin and ofloxacin N-oxide; 4.3%); no first-pass effect could be determined. A third metabolite (the glucuronide derivative) was reported in bile fluid and feces (3.9% [5] ). The limited metabolism of ofloxacin is in contrast to other new fluoroquinolones; some of them have a high degree of biotransformation. The highest number of metabolites in urine was recovered for pefloxacin, amounting to 5% unchanged drug, 20% as norfloxacin and 16% as N-oxide (10) . In summary, ofloxacin pharmacokinetics following oral as well as parenteral administration are different from those of other new quinolones; ofloxacin is excellently absorbed and has a long biological half-life, a high volume of distribution, predominant renal elimination, and only limited biotransformation.
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